Delivering on the promise of science in life sciences
To accelerate progress, the industry will need to focus on strategic imperatives and fundamentally change the drug development paradigm
Add BT as a preferred source
Kavita Rekhraj
CHANGE will persist throughout 2022 and beyond for the life sciences sector in Southeast Asia. Armed with new sources of insights and real-world evidence, companies will be solving problems for diseases that were once thought intractable. New processes adopted during the pandemic to expedite Covid-19 vaccines and therapeutic products will also be applied to accelerate the development of other drugs and treatments.
In the year ahead, the greatest challenge confronting life sciences leaders will be to ensure that they accelerate the valuable progress made – and not revert to old ways. To address this, they will need to focus on three strategic imperatives to capitalise on their digital progress, and fundamentally change the drug development paradigm:
TRENDING NOW
Singapore developer in limbo after Timor-Leste scraps major township project
On the board but frozen out: The Taib family feud tearing Sarawak construction giant apart
MAS to remove mandatory financial advice for complex products for most retail investors
That ‘cheap’ Malaysia condo could cost Singapore buyers far more than they think
